Grant of Exclusive License. Subject to the other applicable terms and conditions of this Agreement, ICN hereby grants to Schering, as of the Effective Date, (a) the exclusive licenses, exclusive even with respect to ICN, to make, have made, develop, use, sell and distribute Product for the treatment of chronic hepatitis C, in each country in the Territory during the Exclusive Period (1) under the Know-How and (2) at Schering's option, under either the ICN Trademark or the Schering Trademark, and (b) the non-exclusive license in and to the Know-How to enable Schering to make, have made, develop, use, sell and distribute the Product for the treatment of chronic hepatitis C in the Territory during the License Period. The exclusive licenses granted in this Section 2.1 (i) are subject to the rights of ICN retained by or reserved to ICN under this Agreement, including without limitation, the rights to manufacture the Product and to distribute, market and sell the Product as provided for in Section 7.1 hereof; (ii) do not include the right to sublicense, except to Affiliates of Schering; (iii) shall prohibit ICN from selling the Product for the treatment of chronic hepatitis C through any distributorship agreements, marketing arrangements or similar agreements other than those in effect on the Effective Date and set forth in Exhibit 2.1 hereto; and (iv) shall prohibit ICN from selling ribavirin in bulk form to any third parties (except pursuant to agreements relating to respiratory syncytial virus and those agreements set forth on Exhibit 2.1).
Appears in 6 contracts
Samples: Stock Purchase Agreement (Icn Pharmaceuticals Inc), Stock Purchase Agreement (Icn Pharmaceuticals Inc), Stock Purchase Agreement (Icn Pharmaceuticals Inc)